Gene/Stem Cell/Molecular Therapy of Craniofacial and Bone Diseases
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 17024
Special Issue Editors
Interests: bone biology; stem cells; molecular therapy; bone regeneration; nanoparticles; bone diseases; craniofacial defects
Interests: bone regeneration; bone tissue engineering; bone regeneration materials; bone defect; bone fusion
Special Issue Information
Dear Colleagues,
Skeletal and craniofacial diseases affect billions of patients each year and are one of main causes of disability and morbidity, resulting in the physical, emotional, and economic hardships of the patients and their families. In recent years, significant progress has been made in the development of novel treatments of bone diseases. Gene therapies have been used to correct, replace, overexpress, or knockout/knockdown the target genes that cause bone diseases. Genetic modification is also known as genetic engineering or recombinant-DNA technology, which includes modifying the existing genes or constructing new genes and incorporating genes into a new organism; transferring genes from one organism to another; or moving, deleting, modifying, or multiplying genes in a living organism. With a deep understanding of stem cell biology, stem cell therapy becomes one of most promising therapeutics, which has been extensively used in human trials in different kinds of bone diseases such as osteoporosis, intervertebral disc degeneration, bone fracture, osteoarthritis and rheumatoid arthritis, bone cancer, and many others. Moreover, nanotechnology, as a revolutionary technology, has become a powerful tool for developing treatments for bone diseases which are difficult to treat with conventional clinical therapies. Nanomaterial-based drug or nuclear acid delivery has potential to increase therapeutic efficiency, reduce adverse effects, and to cure currently incurable bone diseases. Life is now seeking original papers and review articles that describe innovative gene/stem cell/molecular therapies to enhance the therapy of bone diseases in the preclinical as well clinical setting. The design, optimization, and application of such therapies, include, but are not limited to, the following:
Drug delivery approaches for treatment of bone diseases;
Stem cell therapy for skeletal and craniofacial diseases;
Gene silencing, targeting, and editing for therapeutic intervention of craniofacial and bone diseases;
Stem cells, genes, and molecular therapies for skeletal repair and regeneration;
Nanomaterial application for treatment of craniofacial and bone diseases;
New drug discovery and application for craniofacial and bone diseases.
Dr. Shuying Yang
Dr. Keya Mao
Dr. Brian P. Ford
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gene therapy
- stem cells
- drug delivery
- nanomaterials
- bone diseases
- craniofacial
- bone regeneration
- molecular therapy
- target drug delivery
- bone repair
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.